Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GenVec
Gaithersburg, Maryland, United States
- Ownership
- Public · GNVC
- Development stage
- Other
01
Overview
GenVec was a pioneer in the development of adenoviral vector-based gene therapies and vaccines. Its lead program targeting pancreatic cancer failed a late-stage trial several years before its acquisition. The company’s proprietary AdenoVerse™ platform enabled the development of multiple therapeutic candidates across oncology and infectious diseases. Over 3,000 subjects received GenVec therapeutics or vaccines in global clinical trials. In January 2017, Intrexon acquired GenVec to expand its own gene delivery capabilities.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Gene therapy (adenoviral vectors)vaccines
- Industry
- Biotech
02
Partnerships
Novartis – worldwide licensing/collaboration agreement on novel treatments using GenVec’s technology
Beyond the preview
Go deeper on GenVec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenVec.